Lupron Related Published Studies
Well-designed clinical trials related to Lupron (Leuprolide)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. [2011.09]
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. [2011.06]
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.11]
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. [2010.07]
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. [2010.05]
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.03.11]
Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. [2010.03]
Effects of metformin and leuprolide acetate on insulin resistance and
testosterone levels in nondiabetic postmenopausal women: a randomized,
placebo-controlled trial. [2010]
Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. [2009.11]
Leuprolide acetate reduces both in vivo and in vitro ovarian steroidogenesis in infertile women undergoing assisted reproduction. [2008.12.22]
The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. [2008.08]
Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas. [2008.07]
Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. [2007.06]
Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. [2006.02]
Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. [2006.02]
Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. [2006.01]
A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. [2005.05]
Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. [2005.04]
Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. [2004.11]
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. [2004.07.01]
Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. [2004]
Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. [2003.08]
Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. [2002.12]
The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men. [2002.11]
Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. [2002.09]
Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. [2002.07]
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. [2002.04]
Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. [2001.11]
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. [2001.11]
Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. [2001.11]
Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. [2001.10]
Efficacy of ipriflavone in preventing adverse effects of leuprolide. [2001.07]
Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. [2001.02]
Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. [2001.01]
Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? [2000.11]
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. [2000.09]
Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients. [2000.08]
A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. [2000.06]
Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. [2000.04]
Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures. [1999.12]
Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. [1999.08]
Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. [1999.01]
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. [1999]
[Clinical use of leuprolide acetate depot in a group of gynecologic patients in the preoperative period] [1998.11]
Comparison of goserelin and leuprolide in combined androgen blockade therapy. [1998.07]
Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. [1998.06]
Well-designed clinical trials possibly related to Lupron (Leuprolide)
Radiotherapy and short-term androgen deprivation for localized prostate cancer. [2011.07.14]
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation. [2011.07]
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. [2011.05.01]
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010.12]
Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. [2010.12]
Effects of estrogen and testosterone on resting energy expenditure in older men. [2010.12]
Effects of testosterone administration on nocturnal cortisol secretion in healthy older men. [2010.11]
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. [2010.11]
Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. [2010.11]
Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. [2010.10]
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. [2010.09]
Randomized GH trial with two different dosages in combination with a GnRH analogue in short small for gestational age children: effects on metabolic profile and serum GH, IGF1, and IGFBP3 levels. [2010.05]
Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. [2010.02]
A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. [2010.02]
Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy? [2010.02]
LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. [2010.02]
Cognition is not modified by large but temporary changes in sex hormones in men. [2010.01]
Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. [2010.01]
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular
atrophy (JASMITT study): a multicentre, randomised, double-blind,
placebo-controlled trial. [2010]
Effects of testosterone administration on nocturnal cortisol secretion in healthy
older men. [2010]
Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type
determine pulsatile growth hormone secretion in healthy women: studies using
submaximal agonist drive and an estrogen clamp. [2010]
Effects of variations in serum estradiol concentrations on secretory endometrial development and function in experimentally induced cycles in normal women. [2009.12]
Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. [2009.11]
Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. [2009.10]
Regulation of basal, pulsatile, and entropic (patterned) modes of GH secretion in a putatively low-somatostatin milieu in women. [2009.08]
Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. [2009.08]
Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. [2009.08]
Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp. [2009.07]
Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. [2009.06]
Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. [2009.05]
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. [2009.05]
Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. [2009.05]
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. [2009.03]
Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. [2009.03]
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. [2009.02]
Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. [2009.02]
Pharmacologically induced hypogonadism and sexual function in healthy young women and men. [2009.02]
Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy? [2009.01.24]
Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. [2009]
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. [2008.12]
Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist. [2008.12]
Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. [2008.11]
Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. [2008.11]
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. [2008.10]
Endometrial development and function in experimentally induced luteal phase deficiency. [2008.10]
A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium. [2008.09]
Variations in L-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with a gonadotropin-releasing hormone agonist. [2008.09]
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. [2008.06.20]
Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion. [2008.06]
Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. [2008.04]
Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. [2008.03]
The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. [2008.03]
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. [2008.02]
|
